MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction.

Abstract
Gadodiamide injection (Omniscan, Sanofi Winthrop Pharmaceuticals, New York) is a new nonionic MR contrast medium that has been shown in animal studies to provide persistent differential enhancement of myocardial infarction. Because differential enhancement of normal and infarcted myocardium may be useful for the diagnosis and sizing of myocardial infarctions, we assessed the effectiveness of gadodiamide injection in enhancing signal-intensity differences between infarcted and normal myocardium on spin-echo T1-weighted images.Signal intensity of normal and infarcted myocardium, contrast ratio, contrast-to-noise ratio, and signal-to-noise ratio were measured in 12 patients with subacute myocardial infarction (mean, 16 days after diagnosis) before and after injection of contrast medium. Precontrast T1-weighted and T2-weighted images were obtained with a 1.5-T MR imager. T1-weighted images were acquired 5, 15, and 30 min after gadodiamide injection (0.2 mmol/kg) and T1-weighted images with fat saturation were...

This publication has 0 references indexed in Scilit: